Efficacy News and Research

RSS

Anthera to initiate blisibimod Phase 3 program for systemic lupus erythematosus

Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today provided an update on regulatory discussions for the global development of blisibimod.

17 Sep 2012

FDA designates Rib-X's delafloxacin as QIDP for acute bacterial skin and skin structure infections

Rib-X Pharmaceuticals, Inc., today announced that the Food and Drug Administration (FDA) designated delafloxacin as a Qualified Infectious Disease Product (QIDP) for the indications of acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP).

17 Sep 2012

VTT, GE Healthcare enter collaboration for AD research

Scientists from VTT Technical Research Centre of Finland in collaboration with the University of Eastern Finland have recently discovered a serum biochemical signature which predicts progression to Alzheimer's disease months or even years before the first symptoms of the disease occur. The goal of the new collaboration between VTT and GE Healthcare is to validate this biomarker in a large patient cohort as well as to discover novel biomarker candidates.

17 Sep 2012

Biocompatibles, Philips to develop new treatment protocol for trans-arterial embolization

Royal Philips Electronics and Biocompatibles, a BTG international group company, announced a collaboration to advance the use of image guidance to control the delivery of beads during the arterial embolization of hypervascularized tumors today at the annual CIRSE (Cardiovascular and Interventional Radiological Society of Europe) meeting.

15 Sep 2012

Viewpoints: Medicaid's role in lowering uninsured rate; Need to protect physicians 'compelled by conscience' to provide abortions

The number of Americans who lack health insurance declined last year, the first drop since 2007. This is, in large part, the result of the health care reform law and better coverage under public programs like Medicaid. This also shows why repealing the health care law or revamping and shrinking Medicaid, as many Republicans want to do, would be disastrous moves.

14 Sep 2012

FDA clears Tangent Medical’s NovaCath Secure IV Catheter System

Tangent Medical, an innovator in IV therapy products, today announced it has received FDA 510(k) clearance for the NovaCath Secure IV Catheter System, a product designed to set new standards in peripheral IV catheter design, functionality and performance.

14 Sep 2012

Sun-protection counseling by medical staff ineffective

Research shows that sun-protection behaviors carried out by 9 to 16-year-old children are not significantly influenced by sun-protection counseling by pediatricians.

13 Sep 2012

Gefitinib shows promise in Chinese lung cancer patients

Gefitinib improves progression-free survival, overall response, and health-related quality of life over carboplatin/paclitaxel for first-line advanced non-small-cell lung cancer treatment, a study indicates.

13 Sep 2012

Crizotinib may be effective treatment option for NSCLC subtype

Phase I trial results show that the chemotherapy drug crizotinib may be fast-acting and produce long-lasting treatment responses in patients with anaplastic lymphoma receptor tyrosine kinase-positive non-small-cell lung cancer.

13 Sep 2012

Nature examines efforts to combat antibiotic resistance in India

Nature examines efforts to combat antibiotic resistance in India, writing, "Antibiotic resistance is a problem worldwide, but is particularly worrying in India, where hospital standards are inconsistent and antibiotics are readily available over the counter at pharmacies."

13 Sep 2012

Biodel initiates BIOD-123 Phase 2 trial in Type 1 diabetes

Biodel Inc. today announced the initiation of a Phase 2 clinical trial of its proprietary recombinant insulin (RHI)-based ultra-rapid-acting mealtime insulin candidate, BIOD-123.

13 Sep 2012

Young smokers face psychological difficulties of quitting as adults

Abstinence from smoking seems to affect teens differently than adults in a couple ways, but a new study provides evidence that most of the psychological difficulties of quitting are as strong for relatively new, young smokers as they are for adults who have been smoking much longer.

13 Sep 2012

AtriCure receives FDA approval for surgical treatment of atrial fibrillation

AtriCure, Inc., the leader in surgical ablation for the treatment of Atrial Fibrillation, has announced FDA approval of the ABLATE Post Approval Study (PAS).

13 Sep 2012

Glenmark's GBR 500 enters Phase II clinical development for severe ulcerative colitis

Glenmark Pharmaceuticals S.A. (GPSA), a wholly-owned subsidiary of Glenmark Pharmaceuticals Limited (GPL), announced today that GBR 500 has entered Phase II clinical development.

13 Sep 2012

Genzyme receives FDA approval for AUBAGIO to treat relapsing forms of MS

Genzyme, a Sanofi company, announced today that the U.S. Food and Drug Administration (FDA) has approved AUBAGIO (teriflunomide) as a new once-daily, oral treatment indicated for patients with relapsing forms of multiple sclerosis (MS).

13 Sep 2012

Roughly two in five women in the U.S. do not use any form of birth control: Survey

Roughly two in five women in the United States do not use any form of birth control and many underestimate their risk for pregnancy, according to a recent survey about contraceptive practices in the United States.

13 Sep 2012

Positive data from Tetraphase Pharmaceuticals’ eravacycline Phase 2 trial on cIAI

Tetraphase Pharmaceuticals, Inc., a clinical-stage life science company developing novel antibiotics effective against antibiotic-resistant bacteria, presented new, positive Phase 2 clinical data on its lead drug candidate, eravacycline (TP-434), on September 11, 2012, at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, CA.

13 Sep 2012

Breakthrough for dengue vaccine development

A live-attenuated vaccine against the four strains of dengue virus known as CYD-TDV has demonstrated promising efficacy in a phase IIb trial.

12 Sep 2012

Combination chemotherapy confirmed viable for penile cancer

A combination of cisplatin and 5-fluorouracil is an effective and well-tolerated regimen for patients with squamous cell carcinoma of the penis, show study findings.

12 Sep 2012

MD Anderson joins API’s Actimab-A Phase I/II trial in acute myeloid leukemia

Actinium Pharmaceuticals, Inc. (API), a biopharmaceutical company that develops innovative targeted payload immunotherapeutics, announced that MD Anderson Cancer Center in Houston, Texas has joined the Company's ongoing Phase I/II trial in newly diagnosed patients with acute myeloid leukemia (AML).

12 Sep 2012